Hansen Medical Announces Initiation of Sell-Side Coverage by Wm Smith & Co.
MOUNTAIN VIEW, CA -- (Marketwired) -- 06/25/13 -- Hansen Medical,
Inc. (NASDAQ: HNSN), a global leader in intravascular robotics, today
announced that Wm Smith & Co. has initiated sell-side coverage of
Hansen Medical. The report was authored by Sherry Grisewood, CFA.
About Analyst Coverage of Hansen Medical
Hansen Medical is followed
by several analysts, including Wm Smith & Co. Any opinions,
estimates, forecasts or statements regarding Hansen Medical's
performance made by Wm Smith & Co. or other analysts are theirs alone
and do not represent opinions, estimates, forecasts or statements of
Hansen Medical or its management. This press release does not imply
Hansen Medical's endorsement of or concurrence with the information,
conclusions or recommendations of Wm Smith & Co. or any other
About Hansen Medical, Inc.
Hansen Medical, Inc., based in Mountain
View, California, is the global leader in intravascular robotics,
developing products and technology designed to enable the accurate
positioning, manipulation and control of catheters and catheter-based
technologies. The Company's Magellan(TM) Robotic System, Magellan
Robotic Catheter and related accessories, which are intended to
facilitate navigation to anatomical targets in the peripheral
vasculature and subsequently provide a conduit for manual placement
of therapeutic devices, have undergone both CE marking and 510(k)
clearance and are commercially available in the European Union, and
the U.S. In the European Union, the Company's Sensei(R) X Robotic
Catheter System and Artisan Control Catheter are cleared for use
during electrophysiology (EP) procedures, such as guiding catheters
in the treatment of atrial fibrillation (AF), and the Lynx(R) Robotic
Ablation Catheter is cleared for the treatment of AF. This robotic
catheter system is compatible with fluoroscopy, ultrasound, 3D
surface map and patient electrocardiogram data. In the U.S. the
Company's Sensei X Robotic Catheter System and Artisan Control
Catheter were cleared by the U.S. Food and Drug Administration for
manipulation and control of certain mapping catheters in EP
procedures. In the United States, the Sensei System is not approved
for use in
guiding ablation procedures; this use remains
experimental. The U.S. product labeling therefore provides that the
safety and effectiveness of the Sensei X System and Artisan Control
Catheter for use with cardiac ablation catheters in the treatment of
cardiac arrhythmias, including AF, have not been established.
Additional information can be found at www.hansenmedical.com.
About Wm Smith & Co.
Wm Smith & Co. is an independent research
company providing objective, fundamental equity research on a variety
of companies to a select group of institutional clients from both the
traditional and alternative investment arena. Founded in 1992, the
firm is headquartered in Colorado.
Peter J. Mariani
Chief Financial Officer
Hansen Medical, Inc.
FTI Consulting, Inc.
Press spacebar to pause and continue. Press esc to stop.